Elite 50% OFF Act now – get top investing tools Register Now!

RAPT Therapeutics, Inc.

Contributing Author

Recent Articles by RAPT Therapeutics, Inc.

Nov-06	RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights RAPT GlobeNewswire
Nov-04	RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences RAPT GlobeNewswire
Oct-27	RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies RAPT GlobeNewswire
Oct-21	RAPT Therapeutics Announces Pricing of Public Offering of Common Stock RAPT GlobeNewswire
Oct-21	RAPT Therapeutics Announces Proposed Public Offering of Common Stock RAPT GlobeNewswire
Oct-20	RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria RAPT GlobeNewswire
Oct-19	RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) RAPT GlobeNewswire
Sep-29	RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy RAPT GlobeNewswire
Aug-27	RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences RAPT GlobeNewswire
Aug-07	RAPT Therapeutics Reports Second Quarter 2025 Financial Results RAPT GlobeNewswire
Jun-23	RAPT Therapeutics Names Two Industry Veterans to its Board of Directors RAPT GlobeNewswire
Jun-13	RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split RAPT GlobeNewswire
Jun-04	RAPT Therapeutics to Participate in Upcoming Investor Conferences RAPT GlobeNewswire
May-08	RAPT Therapeutics Reports First Quarter 2025 Financial Results RAPT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.